This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
26 Dec 2011

Alopexx & Provenance Ink Deal for Anticancer Immunotherapeutic

Alopexx has agreed to an $8 million financing deal with Provenance to facilitate development of the latter’s anticancer candidate.

U.S. healthcare company Alopexx Enterprises has agreed to an $8 million financing deal with biotech Provenance Biopharmaceuticals’ to facilitate development of the latter’s early clinical-stage lead anticancer candidate DI-Leu16-IL2.

 

The firms are in addition establishing a new company, Alopexx Oncology, to manage development of the drug.

 

DI-Leu16-IL2 is a de-immunized form of an anti-CD20 antibody, Leu16, genetically fused to interleukin 2 (IL2). The immunotherapeutic is being studied for the treatment of non-Hodgkin lymphoma and other forms of hematological cancer and is currently in an investigator-sponsored Phase I trial.

 

Related News